CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: GFOD2 (ImmuneEditome ID:81577)

1. Gene summary of enriched editing regions for GFOD2

check button Gene summary
Gene informationGene symbol

GFOD2

Gene ID

81577

GeneSynonyms-
GeneCytomap

16q22.1

GeneTypeprotein-coding
GeneDescriptionglucose-fructose oxidoreductase domain-containing protein 2|glucose-fructose oxidoreductase domain containing 2
GeneModificationdate20230517
UniprotIDQ3B7J2;A0A087WTD9;A0A087WT49
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:67676207-67680414:-ENST00000602627.1ENSG00000141098.11GFOD2exonicMIRb,AluSp,AluSx1,AluSq2,AluSg4,L2,AluJr,MLT2D,AluJochr16:67676207-67680414:-.alignment
chr16:67681409-67684699:-ENST00000602855.2ENSG00000141098.11GFOD2exonicAluSq2,AluSg,AluSz,AluJb,AluJr,AluSx,MER5A,L2bchr16:67681409-67684699:-.alignment
chr16:67702648-67702874:-ENST00000268797.10ENSG00000141098.11GFOD2intronicAluSxchr16:67702648-67702874:-.alignment
chr16:67702648-67702874:-ENST00000602279.2ENSG00000141098.11GFOD2intronicAluSxchr16:67702648-67702874:-.alignment
chr16:67702648-67702874:-ENST00000602377.1ENSG00000141098.11GFOD2intronicAluSxchr16:67702648-67702874:-.alignment
chr16:67702648-67702874:-ENST00000602496.1ENSG00000141098.11GFOD2intronicAluSxchr16:67702648-67702874:-.alignment
chr16:67702648-67702874:-ENST00000602855.2ENSG00000141098.11GFOD2intronicAluSxchr16:67702648-67702874:-.alignment


Top

2. Tumor-specific enriched editing regions for GFOD2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr16:67681409-67684699:-BRCAEER2.9775e-20image
ENSG00000141098.11,GFOD2BRCAEAG4.3777e-19image
chr16:67681409-67684699:-COADEER2.4621e-05image
ENSG00000141098.11,GFOD2COADEAG5.9436e-06image
chr16:67681409-67684699:-HNSCEER9.9700e-12image
ENSG00000141098.11,GFOD2HNSCEAG1.0148e-06image
chr16:67681409-67684699:-KIRCEER2.7694e-05image
ENSG00000141098.11,GFOD2KIRCEAG7.9919e-05image
chr16:67681409-67684699:-KIRPEER1.4015e-03image
ENSG00000141098.11,GFOD2KIRPEAG2.8734e-03image
chr16:67681409-67684699:-LUADEER3.3565e-06image
ENSG00000141098.11,GFOD2LUADEAG8.7125e-06image
chr16:67681409-67684699:-LUSCEER1.4939e-07image
ENSG00000141098.11,GFOD2LUSCEAG1.0149e-07image
chr16:67681409-67684699:-THCAEER3.0896e-21image
ENSG00000141098.11,GFOD2THCAEAG1.8769e-19image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000141098.11,GFOD2KIRCPathEAG2.3474e-032.5099e-040.1637image
chr16:67681409-67684699:-KIRCPathEER7.8779e-046.6950e-050.1780image
chr16:67681409-67684699:-KIRPPathEER1.7954e-046.1075e-050.2640image
ENSG00000141098.11,GFOD2KIRPPathEAG1.2311e-034.4250e-040.2313image
ENSG00000141098.11,GFOD2PAADPathEAG2.3154e-033.3560e-020.1731image
chr16:67681409-67684699:-PAADPathEER1.5346e-033.3261e-020.1745image
chr16:67681409-67684699:-READPathEER4.6737e-022.1159e-02-0.2363image
chr16:67681409-67684699:-SKCMPathEER4.6020e-021.1640e-020.1327image
ENSG00000141098.11,GFOD2THCAPathEAG4.9317e-044.9953e-030.1342image
chr16:67681409-67684699:-THCAPathEER4.0313e-043.6430e-030.1406image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for GFOD2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:67681409-67684699:-LGGEERENSG00000141098,GFOD2-0.48461.8831e-263.5731e-26-0.4431imageNBCCIP;DICER1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CELF2;CSTF2T;DGCR8;EWSR1;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2NAMacrophages_M0GSVA_HALLMARK_SPERMATOGENESIS
chr16:67681409-67684699:-LGGEERENSG00000174437,ATP2A2-0.40456.1987e-181.1944e-21-0.4041imageNBCCIP;DICER1;DKC1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CELF2;CSTF2T;DGCR8;EWSR1;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2ATP2A2Macrophages_M2GSVA_HALLMARK_HEDGEHOG_SIGNALING
chr16:67681409-67684699:-GBMEERENSG00000141098,GFOD2-0.45997.6706e-061.0908e-08-0.4417imageNBCCIP;DICER1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CELF2;CSTF2T;DGCR8;EWSR1;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2NAMacrophages_M0GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr16:67681409-67684699:-GBMEERENSG00000073536,NLE1-0.44781.5860e-051.4340e-08-0.4385imageNBCCIP;DICER1;DKC1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CSTF2T;DGCR8;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr16:67681409-67684699:-GBMEERENSG00000072832,CRMP1-0.44421.7080e-058.3245e-08-0.4169imageNBCCIP;DKC1;RBFOX2;TAF15;ZNF184;CSTF2T;DGCR8;EWSR1;FBL;FMR1;HNRNPL;IGF2BP1;IGF2BP3;U2AF2NAMonocytesGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr16:67681409-67684699:-GBMEERENSG00000109576,AADAT-0.43363.2061e-056.4906e-08-0.4200imageNDKC1;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;BUD13;CELF2;CSTF2T;DGCR8;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr16:67681409-67684699:-GBMEERENSG00000095370,SH2D3C-0.42704.0023e-052.9565e-07-0.4002imageNDKC1;MSI2;RBFOX2;TAF15;ZNF184;CELF2;CSTF2T;DGCR8;EWSR1;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;U2AF2NAMacrophages_M0GSVA_HALLMARK_HEDGEHOG_SIGNALING
chr16:67681409-67684699:-GBMEERENSG00000101098,RIMS4-0.42624.5523e-053.6310e-08-0.4273imageNDICER1;DKC1;RBFOX2;SRSF1;SRSF9;TAF15;ZNF184;CSTF2T;DGCR8;EWSR1;FBL;FMR1;IGF2BP1;IGF2BP3;SRSF7;U2AF2RIMS4MonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr16:67681409-67684699:-GBMEERENSG00000114631,PODXL2-0.42115.6756e-052.4641e-07-0.4027imageNBCCIP;DICER1;DKC1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;BUD13;CSTF2T;DGCR8;FBL;FMR1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2PODXL2MonocytesGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr16:67681409-67684699:-GBMEERENSG00000113758,DBN1-0.41976.3337e-051.3120e-07-0.4110imageNBCCIP;DICER1;DKC1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CELF2;CSTF2T;DGCR8;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2NAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM

More results



Top

4. Enriched editing regions and immune related splicing for GFOD2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:67681409-67684699:-
GBMEERIRENSG00000101294.12chr2031547381:31548793:31549028:31549114-0.41052.3554e-041.1924e-08-0.4488imageNBCCIP;DICER1;DKC1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CELF2;CSTF2T;DGCR8;EWSR1;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2HM13NeutrophilsGSVA_HALLMARK_BILE_ACID_METABOLISM
chr16:67681409-67684699:-
GBMEERIRENSG00000106077.14chr773736093:73737110:73737220:73737360-0.44241.4211e-041.0350e-08-0.4424imageNPRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CSTF2T;DGCR8;FBL;FMR1;GTF2F1;HNRNPK;IGF2BP3;PCBP2;SRSF7;U2AF2NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr16:67681409-67684699:-
GBMEERIRENSG00000182196.9chr12122980927:122980987:122981128:122981205-0.32825.8061e-039.5502e-07-0.4058imageNBCCIP;DICER1;DKC1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CELF2;CSTF2T;DGCR8;FBL;FMR1;GTF2F1;HNRNPK;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2NAMonocytesGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr16:67681409-67684699:-
GBMEERMEXENSG00000137094.10chr934989744:34989831:34990347:34990611:34990670:34990812:34993199:349933320.28011.7810e-024.9164e-060.4066imageNDKC1;MSI2;PRPF8;RBFOX2;SRSF1;TAF15;BUD13;CSTF2T;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2NAMacrophages_M0GSVA_HALLMARK_SPERMATOGENESIS
ENSG00000141098.11,GFOD2
GBMEAGIRENSG00000182196.9chr12122980927:122980987:122981128:122981205-0.34722.8233e-034.0560e-07-0.4182imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3B4;SLBP;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_FATTY_ACID_METABOLISM
ENSG00000141098.11,GFOD2
GBMEAGIRENSG00000106077.14chr773736093:73737110:73737220:73737360-0.43292.3663e-042.5067e-08-0.4318imageNADAR;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SF3B4;SLBP;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
ENSG00000141098.11,GFOD2
GBMEAGIRENSG00000101294.12chr2031547381:31548793:31549028:31549114-0.41951.6299e-044.1014e-09-0.4613imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3B4;SLBP;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184HM13NeutrophilsGSVA_HALLMARK_BILE_ACID_METABOLISM
chr16:67681409-67684699:-
KICHEERIRENSG00000159079.14chr2132601666:32601973:32603160:32603292-0.52482.7829e-022.7954e-06-0.5984imageNBCCIP;DICER1;DKC1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CELF2;CSTF2T;DGCR8;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2NAMast_cells_activated
ENSG00000141098.11,GFOD2
KICHEAGIRENSG00000159079.14chr2132601666:32601973:32603160:32603292-0.52473.7901e-022.7954e-06-0.5984imageNAUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3B4;SLBP;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YWHAG;ZNF184NAMast_cells_activated
chr16:67681409-67684699:-
KIRCEERIRENSG00000164985.10chr915464065:15465580:15466747:154668590.23252.9675e-032.1257e-160.4158imageNBCCIP;DICER1;DKC1;MSI2;PRPF8;RBFOX2;SF3B4;SRSF1;SRSF9;TAF15;U2AF1;ZNF184;BUD13;CELF2;CSTF2T;DGCR8;EWSR1;FBL;FMR1;GTF2F1;HNRNPK;HNRNPL;IGF2BP1;IGF2BP3;PCBP2;SRSF7;U2AF2PSIP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for GFOD2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:67676207-67680414:-BLCAEERT_cells_CD4_memory_activated1.5918e-020.3208image
chr16:67681409-67684699:-BLCAEERT_cells_CD4_memory_activated1.0459e-060.2682image
ENSG00000141098.11,GFOD2BLCAEAGT_cells_CD4_memory_activated9.8571e-080.2870image
chr16:67676207-67680414:-BRCAEERDendritic_cells_activated2.4069e-02-0.2364image
chr16:67681409-67684699:-BRCAEERT_cells_regulatory_(Tregs)1.0852e-090.1877image
ENSG00000141098.11,GFOD2BRCAEAGMacrophages_M11.2156e-080.1751image
chr16:67681409-67684699:-CESCEERT_cells_CD83.0434e-020.1618image
ENSG00000141098.11,GFOD2CESCEAGT_cells_CD84.4712e-020.1486image
chr16:67681409-67684699:-CHOLEERB_cells_memory1.3471e-030.5347image
ENSG00000141098.11,GFOD2CHOLEAGMacrophages_M03.0371e-020.3774image
chr16:67681409-67684699:-COADEERT_cells_regulatory_(Tregs)1.2213e-02-0.1639image
ENSG00000141098.11,GFOD2COADEAGNeutrophils9.0304e-040.2160image
chr16:67676207-67680414:-ESCAEERT_cells_CD4_naive5.7444e-030.2972image
chr16:67681409-67684699:-ESCAEERNK_cells_activated1.1119e-020.2002image
ENSG00000141098.11,GFOD2ESCAEAGNK_cells_activated1.0117e-020.2028image
chr16:67681409-67684699:-GBMEERMacrophages_M01.6783e-03-0.2520image
ENSG00000141098.11,GFOD2GBMEAGMacrophages_M02.5872e-03-0.2419image
chr16:67681409-67684699:-HNSCEERMacrophages_M14.0724e-040.1819image
ENSG00000141098.11,GFOD2HNSCEAGMacrophages_M12.0435e-040.1897image
chr16:67681409-67684699:-KICHEERB_cells_naive3.0956e-03-0.3698image
ENSG00000141098.11,GFOD2KICHEAGB_cells_naive3.4375e-03-0.3660image
chr16:67681409-67684699:-KIRCEERMast_cells_resting1.2390e-05-0.2284image
ENSG00000141098.11,GFOD2KIRCEAGMast_cells_resting1.0633e-05-0.2301image
chr16:67681409-67684699:-KIRPEERT_cells_CD4_memory_resting1.5634e-03-0.1994image
ENSG00000141098.11,GFOD2KIRPEAGT_cells_CD4_memory_resting2.1968e-03-0.1924image
ENSG00000141098.11,GFOD2LAMLEAGT_cells_gamma_delta4.3917e-030.2854image
chr16:67681409-67684699:-LGGEERMacrophages_M01.2053e-05-0.1915image
ENSG00000141098.11,GFOD2LGGEAGMacrophages_M04.4290e-05-0.1789image
ENSG00000141098.11,GFOD2LIHCEAGMacrophages_M12.2990e-020.1432image
chr16:67681409-67684699:-LUADEERT_cells_CD81.0479e-050.2440image
ENSG00000141098.11,GFOD2LUADEAGT_cells_CD4_memory_activated3.3842e-050.2282image
chr16:67681409-67684699:-LUSCEERMacrophages_M11.0512e-030.1710image
ENSG00000141098.11,GFOD2LUSCEAGMacrophages_M16.6481e-040.1769image
chr16:67681409-67684699:-OVEERDendritic_cells_activated6.0753e-040.2128image
ENSG00000141098.11,GFOD2OVEAGDendritic_cells_activated1.3822e-030.1974image
chr16:67681409-67684699:-PAADEERDendritic_cells_activated2.4425e-030.2449image
ENSG00000141098.11,GFOD2PAADEAGT_cells_gamma_delta1.9400e-020.1888image
chr16:67681409-67684699:-PCPGEERT_cells_regulatory_(Tregs)3.4112e-030.2240image
ENSG00000141098.11,GFOD2PCPGEAGT_cells_regulatory_(Tregs)4.9257e-030.2135image
chr16:67681409-67684699:-PRADEERT_cells_regulatory_(Tregs)2.6748e-050.1945image
ENSG00000141098.11,GFOD2PRADEAGT_cells_regulatory_(Tregs)4.1350e-040.1631image
chr16:67681409-67684699:-READEERMacrophages_M28.0589e-030.2856image
ENSG00000141098.11,GFOD2READEAGNK_cells_activated3.3491e-020.2296image
chr16:67681409-67684699:-SARCEERMacrophages_M13.0413e-040.2620image
ENSG00000141098.11,GFOD2SARCEAGMacrophages_M12.1524e-030.2225image
chr16:67681409-67684699:-SKCMEERT_cells_CD86.1993e-100.2973image
ENSG00000141098.11,GFOD2SKCMEAGT_cells_CD85.1983e-100.2968image
chr16:67676207-67680414:-STADEERT_cells_follicular_helper2.3815e-020.2259image
chr16:67681409-67684699:-STADEERT_cells_CD4_memory_activated1.4799e-070.2745image
ENSG00000141098.11,GFOD2STADEAGT_cells_CD4_memory_activated7.1406e-080.2800image
chr16:67681409-67684699:-TGCTEERMacrophages_M22.1602e-03-0.2844image
ENSG00000141098.11,GFOD2TGCTEAGMacrophages_M25.0999e-03-0.2573image
chr16:67681409-67684699:-THCAEERDendritic_cells_resting5.1551e-060.2186image
ENSG00000141098.11,GFOD2THCAEAGDendritic_cells_resting1.6582e-060.2268image
chr16:67681409-67684699:-THYMEERT_cells_gamma_delta3.3272e-030.3392image
ENSG00000141098.11,GFOD2THYMEAGT_cells_gamma_delta2.8266e-030.3447image
chr16:67681409-67684699:-UCECEERT_cells_gamma_delta4.9028e-040.3134image
ENSG00000141098.11,GFOD2UCECEAGT_cells_gamma_delta6.4912e-050.3404image
chr16:67681409-67684699:-UCSEEREosinophils3.8681e-02-0.3368image
ENSG00000141098.11,GFOD2UCSEAGT_cells_CD4_memory_resting2.0813e-02-0.3515image
chr16:67681409-67684699:-UVMEERT_cells_CD4_memory_activated1.0773e-030.4055image
ENSG00000141098.11,GFOD2UVMEAGT_cells_CD4_memory_activated2.5374e-030.3739image


Top

6. Enriched editing regions and immune gene sets for GFOD2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr16:67681409-67684699:-BLCAEER2.1914e-020.12771.4922e-020.13566.0994e-030.15254.3629e-050.2257image
ENSG00000141098.11,GFOD2BLCAEAG2.8319e-030.16311.0549e-030.17876.4603e-040.18601.1414e-040.2099image
ENSG00000141098.11,GFOD2STADEAG1.8599e-070.27133.8026e-030.15262.2012e-040.19419.5893e-030.1367image
chr16:67681409-67684699:-STADEER3.6966e-080.28706.6024e-030.14394.1306e-040.18642.0287e-030.1633image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000141098.11,GFOD2ACCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.3594e-020.2748image
chr16:67681409-67684699:-ACCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.7267e-020.2696image
ENSG00000141098.11,GFOD2BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG9.8101e-080.2870image
chr16:67681409-67684699:-BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER7.8832e-090.3146image
chr16:67681409-67684699:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.2556e-190.2730image
ENSG00000141098.11,GFOD2BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.2339e-190.2707image
chr16:67681409-67684699:-CESCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.0517e-05-0.3125image
ENSG00000141098.11,GFOD2CESCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.6349e-040.2666image
ENSG00000141098.11,GFOD2CHOLGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.8921e-020.4064image
chr16:67681409-67684699:-CHOLGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER5.6697e-03-0.4710image
chr16:67681409-67684699:-COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0625e-020.1671image
ENSG00000141098.11,GFOD2COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG6.0623e-03-0.1793image
ENSG00000141098.11,GFOD2ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.4916e-03-0.2375image
chr16:67681409-67684699:-ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.7723e-040.2659image
chr16:67676207-67680414:-ESCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER8.0452e-030.2857image
ENSG00000141098.11,GFOD2GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.7466e-050.3268image
chr16:67681409-67684699:-GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.1800e-050.3460image
ENSG00000141098.11,GFOD2HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.2579e-070.2588image
chr16:67681409-67684699:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.2945e-070.2578image
ENSG00000141098.11,GFOD2KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.5181e-02-0.3071image
chr16:67681409-67684699:-KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.4549e-02-0.3090image
ENSG00000141098.11,GFOD2KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG2.8297e-09-0.3070image
chr16:67681409-67684699:-KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.2523e-09-0.3135image
chr16:67681409-67684699:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER2.7419e-06-0.2921image
ENSG00000141098.11,GFOD2KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1499e-05-0.2730image
ENSG00000141098.11,GFOD2LGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.9247e-08-0.2444image
chr16:67681409-67684699:-LGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.4439e-09-0.2549image
ENSG00000141098.11,GFOD2LIHCGSVA_HALLMARK_GLYCOLYSISEAG1.4444e-030.1996image
chr16:67681409-67684699:-LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.1501e-040.2329image
chr16:67681409-67684699:-LUADGSVA_HALLMARK_MYC_TARGETS_V2EER8.2134e-070.2719image
ENSG00000141098.11,GFOD2LUADGSVA_HALLMARK_MYC_TARGETS_V2EAG4.2804e-060.2522image
ENSG00000141098.11,GFOD2LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9407e-030.1613image
chr16:67681409-67684699:-LUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.2419e-030.1686image
chr16:67681409-67684699:-MESOGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.1102e-020.3400image
ENSG00000141098.11,GFOD2MESOGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.6349e-020.3225image
ENSG00000141098.11,GFOD2OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.5170e-060.2931image
chr16:67681409-67684699:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER7.4385e-070.3035image
chr16:67681409-67684699:-PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.8613e-060.3511image
ENSG00000141098.11,GFOD2PAADGSVA_HALLMARK_P53_PATHWAYEAG7.4475e-050.3147image
chr16:67681409-67684699:-PCPGGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1204e-050.3308image
ENSG00000141098.11,GFOD2PCPGGSVA_HALLMARK_KRAS_SIGNALING_DNEAG5.5360e-040.2606image
ENSG00000141098.11,GFOD2PRADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.4566e-07-0.2409image
chr16:67681409-67684699:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER4.8483e-08-0.2510image
ENSG00000141098.11,GFOD2SARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.5485e-04-0.2725image
chr16:67681409-67684699:-SARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER9.9049e-05-0.2815image
ENSG00000141098.11,GFOD2SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.7661e-100.2991image
chr16:67681409-67684699:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.2241e-110.3115image
ENSG00000141098.11,GFOD2STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6676e-110.3427image
chr16:67681409-67684699:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0169e-130.3724image
ENSG00000141098.11,GFOD2TGCTGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG5.9429e-030.2529image
chr16:67681409-67684699:-TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.1806e-040.3159image
chr16:67681409-67684699:-THCAGSVA_HALLMARK_P53_PATHWAYEER6.7719e-120.3240image
ENSG00000141098.11,GFOD2THCAGSVA_HALLMARK_APOPTOSISEAG7.4102e-130.3341image
chr16:67681409-67684699:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.3489e-05-0.4853image
ENSG00000141098.11,GFOD2THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.0039e-05-0.4613image
chr16:67681409-67684699:-UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER2.7180e-02-0.2017image
ENSG00000141098.11,GFOD2UCECGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.2707e-02-0.2164image
ENSG00000141098.11,GFOD2UCSGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.7668e-020.3602image
chr16:67681409-67684699:-UCSGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.7577e-020.3832image
ENSG00000141098.11,GFOD2UVMGSVA_HALLMARK_APICAL_SURFACEEAG1.0161e-030.4043image
chr16:67681409-67684699:-UVMGSVA_HALLMARK_APICAL_SURFACEEER1.0677e-030.4058image


Top

7. Enriched editing regions and drugs for GFOD2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr16:67681409-67684699:-ACCDMOGEER2.7584e-02-0.2845image
ENSG00000141098.11,GFOD2ACCDMOGEAG2.1643e-02-0.2960image
ENSG00000141098.11,GFOD2BLCAKU.55933EAG5.3292e-08-0.2927image
chr16:67681409-67684699:-BLCACisplatinEER3.0177e-08-0.3027image
chr16:67676207-67680414:-BLCACisplatinEER8.7221e-03-0.3473image
chr16:67681409-67684699:-BRCAJW.7.52.1EER3.3342e-12-0.2138image
ENSG00000141098.11,GFOD2BRCAJW.7.52.1EAG1.9099e-09-0.1844image
chr16:67681409-67684699:-CESCBMS.536924EER4.3532e-07-0.3670image
ENSG00000141098.11,GFOD2CESCBMS.536924EAG3.6647e-06-0.3346image
chr16:67681409-67684699:-CHOLIPA.3EER5.8780e-03-0.4692image
ENSG00000141098.11,GFOD2CHOLAZD6244EAG3.0082e-020.3780image
chr16:67681409-67684699:-COADCisplatinEER8.2330e-03-0.1727image
ENSG00000141098.11,GFOD2COADCisplatinEAG3.0688e-03-0.1932image
ENSG00000141098.11,GFOD2ESCAAKT.inhibitor.VIIIEAG1.9120e-040.2908image
chr16:67676207-67680414:-ESCAEHT.1864EER4.1848e-020.2213image
chr16:67681409-67684699:-ESCAFH535EER7.1979e-050.3086image
ENSG00000141098.11,GFOD2GBMBIBW2992EAG4.5874e-05-0.3233image
chr16:67681409-67684699:-GBMBIBW2992EER4.9960e-05-0.3218image
chr16:67681409-67684699:-HNSCBMS.536924EER4.3865e-08-0.2784image
ENSG00000141098.11,GFOD2HNSCBMS.536924EAG4.7305e-07-0.2553image
chr16:67681409-67684699:-KICHAZD.2281EER8.7900e-04-0.4119image
ENSG00000141098.11,GFOD2KICHAZD.2281EAG8.8718e-04-0.4116image
ENSG00000141098.11,GFOD2KIRCFH535EAG5.0618e-070.2614image
chr16:67681409-67684699:-KIRCBMS.536924EER7.8347e-08-0.2792image
ENSG00000141098.11,GFOD2KIRPCMKEAG8.8322e-070.3044image
chr16:67681409-67684699:-KIRPKIN001.135EER5.9336e-070.3102image
ENSG00000141098.11,GFOD2LAMLBX.795EAG7.5180e-03-0.2685image
ENSG00000141098.11,GFOD2LGGErlotinibEAG7.1183e-16-0.3457image
chr16:67681409-67684699:-LGGErlotinibEER1.8030e-17-0.3632image
chr16:67681409-67684699:-LIHCLenalidomideEER5.1875e-030.1853image
ENSG00000141098.11,GFOD2LIHCGefitinibEAG3.6906e-020.1354image
ENSG00000141098.11,GFOD2LUADLFM.A13EAG1.4139e-040.2099image
chr16:67681409-67684699:-LUADGemcitabineEER6.0687e-04-0.1909image
ENSG00000141098.11,GFOD2LUSCCEP.701EAG3.3034e-04-0.1864image
chr16:67681409-67684699:-LUSCCEP.701EER6.6365e-05-0.2075image
chr16:67681409-67684699:-MESOGNF.2EER1.5799e-02-0.3240image
ENSG00000141098.11,GFOD2MESOGNF.2EAG1.2860e-02-0.3334image
chr16:67681409-67684699:-OVImatinibEER2.2222e-060.2908image
ENSG00000141098.11,GFOD2OVImatinibEAG1.4157e-060.2939image
ENSG00000141098.11,GFOD2PAADCCT007093EAG5.8640e-050.3189image
chr16:67681409-67684699:-PAADCCT007093EER1.1241e-050.3490image
ENSG00000141098.11,GFOD2PCPGAZD6244EAG1.8648e-03-0.2356image
chr16:67681409-67684699:-PCPGEmbelinEER8.1932e-040.2550image
ENSG00000141098.11,GFOD2PRADFH535EAG9.1714e-090.2625image
chr16:67681409-67684699:-PRADEmbelinEER7.1718e-110.2978image
chr16:67681409-67684699:-READCytarabineEER7.0664e-030.2902image
ENSG00000141098.11,GFOD2READCytarabineEAG1.4520e-020.2628image
chr16:67681409-67684699:-SARCAxitinibEER1.9868e-050.3073image
ENSG00000141098.11,GFOD2SARCAxitinibEAG7.6703e-060.3198image
ENSG00000141098.11,GFOD2SKCMLapatinibEAG1.2031e-060.2348image
chr16:67681409-67684699:-SKCMLapatinibEER7.6646e-060.2182image
ENSG00000141098.11,GFOD2STADCisplatinEAG2.9073e-06-0.2443image
chr16:67702648-67702874:-STADAMG.706EER1.9734e-04-0.5327image
chr16:67681409-67684699:-STADCCT007093EER3.0579e-060.2448image
chr16:67676207-67680414:-STADDocetaxelEER1.5637e-02-0.2412image
chr16:67681409-67684699:-TGCTCI.1040EER5.4633e-05-0.3686image
ENSG00000141098.11,GFOD2TGCTCI.1040EAG4.9705e-04-0.3170image
chr16:67681409-67684699:-THCAAZD6244EER1.7991e-22-0.4485image
ENSG00000141098.11,GFOD2THCAAZD6244EAG2.1917e-18-0.4022image
chr16:67681409-67684699:-THYMEmbelinEER2.7083e-040.4141image
ENSG00000141098.11,GFOD2THYMEmbelinEAG5.8392e-040.3930image
ENSG00000141098.11,GFOD2UCECGDC.0449EAG1.8203e-04-0.3202image
chr16:67681409-67684699:-UCECGDC.0449EER3.3688e-04-0.3219image
ENSG00000141098.11,GFOD2UCSGSK269962AEAG2.8704e-03-0.4438image
chr16:67681409-67684699:-UCSGSK269962AEER1.1086e-03-0.5087image
chr16:67681409-67684699:-UVMGNF.2EER1.4213e-03-0.3965image
ENSG00000141098.11,GFOD2UVMGNF.2EAG1.9251e-03-0.3834image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType